A cancer vaccine built from one person's tumor beat the standard drug
In a phase 3 trial of more than 1,100 patients at 157 sites, a melanoma vaccine made from each patient's own tumor cut the risk of the cancer returning, or of death, by 42 percent compared with the immunotherapy Keytruda alone 16.
The vaccine, intismeran, comes from Moderna and Merck. Doctors sequence the tumor, work out what separates it from healthy cells, and send those targets to the immune system as mRNA, which Georgina Long of Melanoma Institute Australia calls a personalized "wanted poster" 16. The results were presented at the European Society for Medical Oncology meeting in Madrid and are set for the New England Journal of Medicine 16. Moderna CEO Stéphane Bancel said the company has worked on it for 10 years, and that most people in the field thought it would never work 23.
What each field noticed (3)
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial
This one explains why the vaccine needs a partner. Long says cancer fools the immune system with a fake friendly handshake; Keytruda blocks the handshake, but it is the same drug for everyone, and the vaccine adds the personal part. Among patients who stayed cancer-free six months after starting treatment, the risk reduction was 58 percent 16.
Read the storySTAT+: After a cancer vaccine’s first success, the race is on to expand the impact
The conversation in Madrid had already moved to adoption. James Larkin of the Royal Marsden said the approach may apply to other tumor types, and Vinod Balachandran of Memorial Sloan Kettering called the field's record a "long and sordid" history that added up to 100 years of failure until now 28.
Read the storyLandmark melanoma vaccine cuts deaths in landmark trial
New Atlas supplies the baseline: with Keytruda alone, about 30 percent of patients relapse in the first two years, and the vaccine's 42 percent cut points toward under 20 percent. It also walks through the neoantigens, the protein markers that let the tumor write its own identikit 101.
Read the story